Selumetinib

Selumetinib (AZD6244) is a drug that was discovered by Array BioPharma and was licensed to AstraZeneca. It is being investigated for the treatment of various types of cancer, such as non-small cell lung cancer (NSCLC).

CAS# 606143-52-6

606143-52-6
Selumetinib

This is Accel Pharmtech, LLC (DUNS number: 833130128)and we welcome all customers and vendors to cooperate business with us to achieve the greatest mutual benefits!

Ariba Network ID: AN01013471473

Email: sales@accelpharmtech.com 

Website: www.accelpharmtech.com

 

Advertisements

CAR-T CANCER IMMUNOTHERAPY TOOK OFF

In a sweeping success for cancer immunotherapy this year, the U.S. Food & Drug Administration approved the first two treatments that use a patient’s own genetically engineered cells to combat specific kinds of blood cancer.
Both new drugs are CAR T-cell immunotherapies, created by injecting an individual’s T cells with DNA that encodes a chimeric antigen receptor (CAR). The CAR proteins jut from the immune cells’ surfaces and direct them to seek and destroy tumor cells.

CAR-T is state of the art, and this is just the beginning.

See more details as below:

https://cen.acs.org/articles/95/i48/year-in-pharma-2017.html#CAR-T-cancer-immunotherapy-took-off

Kymriah
An IV bag of Kymriah, the one-time, $475,000 CAR-T immunotherapy treatment from Novartis, contains a patient’s genetically engineered T cells.——Credit: Novartis

Bayer, Loxo to jointly develop TRK inhibitors

In a deal worth up to $1.5 billion, Bayer and Loxo Oncology will jointly develop two Loxo drug candidates, larotrectinib and LOXO-195, for treating cancers caused by a rare genetic mutation.

Larotrectinib was a breakout star of the American Society for Clinical Oncology conference in June, where researchers revealed that it shrank tumors in 76% of the kids and adults in a small study. LOXO-195, currently in Phase I/II trials, is designed to treat people who develop resistance to first-generation TRK inhibitors like larotrectinib.

Now, Bayer, which some investors view as a second-tier player in oncology, will split U.S. marketing responsibilities with Loxo.

TRK inhibitors

(cr: Chemical & Engineering News )

olaparib

Olaparib (AZD-2281, trade name Lynparza) is an FDA-approved targeted therapy for cancer, developed by KuDOS Pharmaceuticals and later by AstraZeneca. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.

CAS# 763113-22-0

olaparib
olaparib

If you need, please feel free to contact us.

Email: sales@accelpharmtech.com
Website: www.accelpharmtech.com

Elesclomol

Elesclomol (INN, codenamed STA-4783) is a drug that triggers apoptosis (programmed cell death) in cancer cells. It is being developed by Synta Pharmaceuticals and GlaxoSmithKline as a chemotherapy adjuvant, and has received both fast track and orphan drug status from the U.S. Food and Drug Administration for the treatment of metastatic melanoma. CAS# 488832-69-5

elesclomol
elesclomol

If you have any problems, please feel free to contact us. ♥♥♥

Email: sales@accelpharmtech.com
Website: www.accelpharmtech.com

Ubenimex

Ubenimex (INN), also known more commonly as bestatin, is a competitive, reversible protease inhibitor.  It is being studied for use in the treatment of acute myelocytic leukemia. Ubenimex has been found to inhibit the enzymatic degradation of oxytocin, vasopressin, enkephalins, and various other peptides and compounds.  CAS# 58970-76-6 And (2S,3R)-3-Amino-2-hydroxy-4-phenylbutyric acid is the intermediate of  ubenimex. CAS# 59554-14-2

If you need, please feel free to contact us.

 

Email: sales@accelpharmtech.com
Website: www.accelpharmtech.com